<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Problems of Biological Medical and Pharmaceutical Chemistry</journal-id><journal-title-group><journal-title xml:lang="en">Problems of Biological Medical and Pharmaceutical Chemistry</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы биологической, медицинской и фармацевтической химии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1560-9596</issn><issn publication-format="electronic">2587-7313</issn><publisher><publisher-name xml:lang="en">Russkiy Vrach Publishing House</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">637329</article-id><article-id pub-id-type="doi">10.29296/25877313-2024-10-05</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Problems of experimental biology and medicine</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Вопросы экспериментальной биологии и медицины</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Permeability of the blood-brain barrier in toxic parkinsonism</article-title><trans-title-group xml:lang="ru"><trans-title>Проницаемость гематоэнцефалического барьера при токсическом паркинсонизме</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2246-4127</contrib-id><name-alternatives><name xml:lang="en"><surname>Gradinar</surname><given-names>М. М.</given-names></name><name xml:lang="ru"><surname>Градинарь</surname><given-names>М. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assistant, Department of Pharmacology</p></bio><bio xml:lang="ru"><p>ассистент, кафедра фармакологии</p></bio><email>masha.gradinar1995@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5618-7607</contrib-id><name-alternatives><name xml:lang="en"><surname>Chernykh</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Черных</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr.Sc. (Biol.), Associate Professor, Head of the Department of Pharmaceutical Chemistry and Pharmacognosy</p></bio><bio xml:lang="ru"><p>д.б.н., доцент, зав. кафедрой фармацевтической химии и фармакогнозии</p></bio><email>ivchernykh88@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0427-0967</contrib-id><name-alternatives><name xml:lang="en"><surname>Abalenikhina</surname><given-names>Yu. V.</given-names></name><name xml:lang="ru"><surname>Абаленихина</surname><given-names>Ю. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr.Sc. (Med.), Associate Professor, Department of Biological Chemistry</p></bio><bio xml:lang="ru"><p>д.м.н., доцент, профессор кафедры биологической химии</p></bio><email>abalenihina88@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1688-0017</contrib-id><name-alternatives><name xml:lang="en"><surname>Shchulkin</surname><given-names>А. V.</given-names></name><name xml:lang="ru"><surname>Щулькин</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr.Sc. (Med.), Associate Professor, Department of Pharmacology</p></bio><bio xml:lang="ru"><p>д.м.н., доцент, кафедра фармакологии</p></bio><email>alekseyshulkin@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6887-4888</contrib-id><name-alternatives><name xml:lang="en"><surname>Yakusheva</surname><given-names>Е. N.</given-names></name><name xml:lang="ru"><surname>Якушева</surname><given-names>Е. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr.Sc. (Med.), Professor, Head of the Department of Pharmacology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, зав. кафедрой фармакологии</p></bio><email>e.yakusheva@rzgmu.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Ryazan State Medical University named after Academician I.P. Pavlov</institution></aff><aff><institution xml:lang="ru">Рязанский государственный медицинский университет имени академика И.П. Павлова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-10-22" publication-format="electronic"><day>22</day><month>10</month><year>2024</year></pub-date><volume>27</volume><issue>10</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>32</fpage><lpage>37</lpage><history><date date-type="received" iso-8601-date="2024-10-21"><day>21</day><month>10</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-10-21"><day>21</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Russkiy Vrach Publishing House</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ИД "Русский врач"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Russkiy Vrach Publishing House</copyright-holder><copyright-holder xml:lang="ru">ИД "Русский врач"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2029-10-22"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/1560-9596/article/view/637329">https://journals.eco-vector.com/1560-9596/article/view/637329</self-uri><abstract xml:lang="en"><p><bold>Introduction.</bold> Parkinson's disease (PD) is a chronic neurodegenerative disease of the central nervous system with accumulation of alpha-synuclein and degeneration of nigrostriatal neurons. A number of studies have shown that one of the links in the pathogenesis of PD may also be microdamage of blood vessels. However, how these changes affect intercellular contacts of endothelial cells and the permeability of the blood-brain barrier has not yet been studied.</p> <p><bold>The aim of the study.</bold> To study the permeability of the blood-brain barrier and the level of proteins of intercellular contacts in experimental toxic parkinsonism.</p> <p><bold>Material and methods.</bold> The study was performed on male Wistar rats weighing 280-320 g. Toxic parkinsonism was modeled by subcutaneous administration of rotenone at a dose of 2.5 mg/kg 1 time per day for 7 and 28 days. Dopamine levels were determined in the striatum and midbrain by the ELISA method, and the level of intercellular contact proteins occludin, E-cadherin and ZO-1 were analyzed in the cerebral cortex by the western blot. The permeability of the blood-brain barrier was assessed by penetration of Evans blue dye into brain tissue.</p> <p><bold>Results.</bold> The administration of rotenone caused the development of experimental parkinsonism, which manifested itself in a typical clinical picture and a decrease in dopamine levels in the striatum and midbrain on days 7 and 28 of administration. At the same time, there was a decrease in the relative amounts of occludin, E-cadherin and ZO-1. These biochemical changes led to the permeability of the blood-brain barrier to the Evans blue dye on the 7th and 28th days of the experiment, which indicates an increase in the permeability of the blood-brain barrier.</p> <p><bold>Conclusion.</bold> Thus, in rotenone-induced parkinsonism, the permeability of the blood-brain barrier increases, which is caused by a decrease in specific tight junction proteins that form the connection between endothelial cells and the perivascular microenvironment. The results obtained make a significant contribution to modern understanding of the pathogenesis of Parkinson's disease and allow to identify new approaches to its treatment.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Болезнь Паркинсона (БП) – хроническое нейродегенеративное заболевание центральной нервной системы с накоплением альфа-синуклеина и дегенерацией нигростриарных нейронов. В ряде исследований показано, что одним из звеньев патогенеза БП может также являться микроповреждение сосудов. Однако влияние данных изменений на межклеточные контакты эндотелиальных клеток и проницаемость гематоэнцефалического барьера на данный момент не изучено.</p> <p><bold>Цель исследования </bold>– оценить проницаемость гематоэнцефалического барьера и уровень белков межклеточных контактов при экспериментальном токсическом паркинсонизме.</p> <p><bold>Материал и методы. </bold>Работа проводилась на крысах самцах Wistar массой 280–320 г. Токсический паркинсонизм моделировали путем инъекций ротенона подкожно в дозе 2,5 мг/кг 1 раз в сутки на протяжении 7 и 28 суток. В стриатуме и среднем мозге определяли уровень дофамина методом иммуноферментного анализа, в коре больших полушарий анализировали уровень белков межклеточных контактов окклюдина, E-кадгерина и ZO-1 методом вестерн-блот. Проницаемость гематоэнцефалического барьера оценивали по проникновению в ткань мозга красителя синего Эванса.</p> <p><bold>Результаты. </bold>Введение ротенона вызывало развитие экспериментального паркинсонизма, что проявлялось характерной клинической картиной и уменьшением содержания дофамина в стриатуме и среднем мозге на 7-е и 28-е сутки введения. При этом отмечалось снижение относительного количества окклюдина, E-кадгерина и ZO-1. Данные биохимические изменения приводили к проницаемости гематоэнцефалического барьера для красителя синего Эванса на 7-е и 28-е сутки эксперимента, что свидетельствует о повышении проницаемости гематоэнцефалического барьера.</p> <p><bold>Вывод. </bold>При ротенон-индуцированном паркинсонизме увеличивается проницаемость гематоэнцефалического барьера, что обусловлено снижением специфических белков плотных межклеточных контактов, формирующих соединение между эндотелиальными клетками и периваскулярным микроокружением.</p></trans-abstract><kwd-group xml:lang="en"><kwd>parkinsonism</kwd><kwd>rotenone</kwd><kwd>blood-brain barrier</kwd><kwd>occludin</kwd><kwd>E-cardherin</kwd><kwd>ZO-1</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>паркинсонизм</kwd><kwd>ротенон</kwd><kwd>гематоэнцефалический барьер</kwd><kwd>окклюдин</kwd><kwd>Е-кардгерин</kwd><kwd>ZO-1</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Akhmetzhanov V.K., Shashkin Ch.S., Kerimbayev T.T. Parkinson's disease. Diagnostic criteria. Differential diagnosis. Journal Neurosurgery and Neurology of Kazakhstan. 2016; 4(45): 18–25. (In Russ.) URL: https://cyberleninka.ru/article/n/bolezn-parkinsona-kriterii-diagnostiki-differentsialnaya-diagnostika</mixed-citation><mixed-citation xml:lang="ru">Ахметжанов В.К., Шашкин Ч.С., Керимбаев Т.Т. Болезнь Паркинсона. Критерии диагностики. Дифференциальная диагностика. Журнал «Нейрохирургия и неврология Казахстана». 2016; 4(45): 18–25. URL: https://cyberleninka.ru/article/n/bolezn-parkinsona-kriterii-diagnostiki-differentsialnaya-diagnostika</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>van der Mark M., Brouwer M., Kromhout H., Nijssen P. et al. Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ Health Perspect. 2012; 120(3): 340–347. DOI:10.1289/ehp.1103881.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sherer T.B., Richardson J.R., Testa C.M. et al. Mechanism of toxicity of pesticides acting at complex I: relevance to environmental etiologies of Parkinson's disease. J Neurochem. 2007; 100(6): 1469–1479. DOI:10.1111/j.1471-4159.2006.04333.x.</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Agency Toxic Subst. Dis. Registry (ATSDR). Toxicological profile for toxaphene. US Dep. Health Hum. Serv., Atlanta, Ga. 2010. http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=548&amp;tid=99.</mixed-citation><mixed-citation xml:lang="ru">Agency Toxic Subst. Dis. Registry (ATSDR). Toxicological profile for toxaphene. US Dep. Health Hum. Serv., Atlanta, Ga. 2010. http://www.atsdr.cdc.gov/toxprofiles/tp.asp?id= 548&amp;tid=99.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Pan-Montojo F., Schwarz M., Winkler C. et al. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep. 2012;2:898. DOI:10.1038/srep00898.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Tanner C.M., Kamel F., Ross G.W. et al. Rotenone, paraquat, and Parkinson's disease. Environ Health Perspect. 2011; 119(6): 866–872. DOI:10.1289/ehp.1002839.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Desai B.S., Monahan A.J., Carvey P.M., Hendey B. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplant. 2007; 16(3): 285–299. DOI:10.3727/000000007783464731.</mixed-citation></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Chernykh I.V., Shchulkin A.V., Mylnikov P.Yu. et al. Functional activity of P-glycoprotein in blood-brain barrier during experimental Parkinson's syndrome. I.P. Pavlov Russian Medical Biological Herald. 2019; 27(2): 150–159 (In Russ.). DOI: 10.23888/PAVLOVJ2019272150-159.</mixed-citation><mixed-citation xml:lang="ru">Черных И.В., Щулькин А.В., Мыльников П.Ю. и др. Функциональная активность гликопротеина-p в гематоэнцефалическом барьере на фоне экспериментального паркинсонического синдрома. Российский медико-биологический вестник им. академика И.П. Павлова. 2019; 27(2): 150–159. DOI: 10.23888/PAVLOVJ2019272150-159.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Chernykh I.V., Shchulkin A.V., Gatsanoga M.V. et al. Functional activity of P-glycoprotein with underlying brain ischemia. Science of the young (Eruditio Juvenium). 2019; 7(1): 46–52 (In Russ.). DOI:10.23888/HMJ20197146-52.</mixed-citation><mixed-citation xml:lang="ru">Черных И.В., Щулькин А.В., Гацанога М.В. и др. Функциональная активность гликопротеина-P на фоне ишемии головного мозга. Наука молодых (Eruditio Juvenium). 2019; 7(1): 46–52. DOI:10.23888/HMJ20197146-52.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Voronkov D.N., Dikalova Yu.V., Khudoerkov R.M. et. al. Brain nigrostriatal system changes in rotenone-induced parkinsonism (quantitative immune-morphological study). Annals of Neurology 2013; 7(2): 34–38. (In Russ.). URL: https://cyberleninka.ru/article/n/izmeneniya-v-nigrostriatnyh obrazovaniyah-mozga-pri-modelirovanii-parkinsonizma-indutsirovannogo-rotenonom-kolichestvennoe.</mixed-citation><mixed-citation xml:lang="ru">Воронков Д.Н., Дикалова Ю.В., Худоерков Р.М. и др. Изменения в нигростриатных образованиях мозга при моделировании паркинсонизма, индуцированного ротеноном (количественное иммуноморфологическое исследование). Анналы неврологии. 2013; 7(2): 34–38. URL: https://cyberleninka.ru/article/n/izmeneniya-v-nigrostriatnyh obrazovani-yah-mozga-pri-modelirovanii-parkinsonizma-indutsirovannogo-rotenonom-kolichestvennoe.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Mironov A.N. Guidelines for conducting preclinical studies of medicines. Part one. M.: Vulture and K, 2012. 944 p.12. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Миронов А.Н. Руководство по проведению доклинических исследований лекарственных средств. Часть первая. М.: Гриф и К, 2012. 944 с.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><mixed-citation>Jin Z., Ke J., Guo P. et al. Quercetin improves blood-brain barrier dysfunction in rats with cerebral ischemia reperfusion via Wnt signaling pathway. Am J Transl Res. 2019; 11(8): 4683–4695. Published 2019 Aug 15.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Wang Q., Deng Y., Huang L. et al. Hypertonic saline downregulates endothelial cell-derived VEGF expression and reduces blood-brain barrier permeability induced by cerebral ischaemia via the VEGFR2/eNOS pathway. Int J Mol Med. 2019; 44(3): 1078–1090. DOI:10.3892/ijmm.2019.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Begley D.J. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004; 10(12): 1295–1312. DOI:10.2174/1381612043384844.</mixed-citation></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Sharif A.E., Abdurashitov A.S., Namykin A.A. et. al. Changes in Blood-Brain Barrier Permeability under the Influence of Loud Sound. Izv. Saratov Univ. (N. S.), Ser. Chemistry. Biology. Ecology. 2019; 19(3): 312−321 (In Russ.). DOI: 10.18500/1816-9775-2019-19-3-312-321.</mixed-citation><mixed-citation xml:lang="ru">Шариф А.Е., Абдурашитов А. С., Намыкин А. А. и др. Изменения проницаемости гематоэнцефалического барьера под воздействием громкого звука. Изв. Сарат. ун-та. Нов. сер. Сер. Химия. Биология. Экология. 2019; 19(3): 312−321. DOI: 10.18500/1816-9775-2019-19-3-312-321.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Sweeney M.D., Zhao Z., Montagne A. et al. Blood-Brain Barrier: From Physiology to Disease and Back. Physiol Rev. 2019; 99(1): 21–78. DOI:10.1152/physrev.00050.2017.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Tornavaca O., Chia M., Dufton N. et al. ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. J Cell Biol. 2015; 208(6): 821–838. DOI:10.1083/jcb.201404140.</mixed-citation></ref></ref-list></back></article>
